Last reviewed · How we verify

NCT03793192: PACE2

Promoting Activity After COPD Exacerbations, Aim 2

Terminated NA Last updated 20 January 2025
What this trial tests

NA trial testing PACE2 Intervention in Chronic Obstructive Pulmonary Disease in 7 participants. Terminated before completion.

Timeline
18 March 2019
Primary endpoint
8 April 2022
8 April 2022

Quick facts

Lead sponsorUniversity of Illinois at Chicago
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposeother
Enrollment7
Start date18 March 2019
Primary completion8 April 2022
Estimated completion8 April 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Illinois at Chicago

Who can join

18 and older, any sex, with Chronic Obstructive Pulmonary Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized controlled pilot study involving patients with chronic obstructive pulmonary disease (COPD) recently discharged from the hospital will evaluate the feasibility and efficacy of a home-based mobile-health supported physical activity promotion program.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Interventions for promoting physical activity in people with chronic obstructive pulmonary disease (COPD).
    Burge AT, Cox NS, Abramson MJ, Holland AE. · · 2020 · cited 87× · PMID 32297320 · DOI 10.1002/14651858.cd012626.pub2

Verify or expand the search:

Other recruiting trials for Chronic Obstructive Pulmonary Disease

Currently open trials in the same condition.

Other University of Illinois at Chicago trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03793192.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing